Efficacy and safety of fixed-dose combinations of aclidinium bromide/formoterol fumarate: the 24-week, randomized, placebo-controlled AUGMENT COPD study

Benzer Materyaller

• Aclidinium bromide in fixed-dose combination with formoterol fumarate in the management of COPD: an update on the evidence base
  Yazar:: D’Urzo, Anthony D., ve diğerleri
  Baskı/Yayın Bilgisi: (2019)
• Aclidinium bromide and formoterol fumarate as a fixed-dose combination in COPD: pooled analysis of symptoms and exacerbations from two six-month, multicentre, randomised studies (ACLIFORM and AUGMENT)
  Yazar:: Bateman, Eric D., ve diğerleri
  Baskı/Yayın Bilgisi: (2015)
• Efficacy and safety of aclidinium bromide/formoterol fumarate fixed-dose combinations compared with individual components and placebo in patients with COPD (ACLIFORM-COPD): a multicentre, randomised study
  Yazar:: Singh, Dave, ve diğerleri
  Baskı/Yayın Bilgisi: (2014)
• Aclidinium bromide/formoterol fixed-dose combination therapy for COPD: the evidence to date
  Yazar:: Moitra, Subhabrata, ve diğerleri
  Baskı/Yayın Bilgisi: (2015)
• Cost versus utility of aclidinium bromide 400 µg plus formoterol fumarate dihydrate 12 µg compared to aclidinium bromide 400 µg alone in the management of moderate-to-severe COPD
  Yazar:: Ramos, Mafalda, ve diğerleri
  Baskı/Yayın Bilgisi: (2016)